Vitamin E protects Wistar rats from chlorpyrifos-induced increase in erythrocyte osmotic fragility

2010 ◽  
Vol 48 (12) ◽  
pp. 3477-3480 ◽  
Author(s):  
Suleiman Folorunsho Ambali ◽  
Joseph Olusegun Ayo ◽  
Samuel Adeniyi Ojo ◽  
King A. Nelson Esievo
2019 ◽  
Vol 28 (5) ◽  
pp. 1275-1279
Author(s):  
Emmanuel Vandi Tizhe ◽  
Najume Dogon-Giginya Ibrahim ◽  
Mohammed Yakasai Fatihu ◽  
Suleiman Folorunsho Ambali ◽  
Ikechukwu Onyebuchi Igbokwe ◽  
...  

2017 ◽  
Vol 07 (03) ◽  
pp. 71-85 ◽  
Author(s):  
Ejike Daniel Eze ◽  
Yusuf Tanko ◽  
Ahmed Abubakar ◽  
Sheu Oluwadare Sulaiman ◽  
Karimah Mohammed Rabiu ◽  
...  

2014 ◽  
Vol 54 (5) ◽  
pp. 280
Author(s):  
Agus Fitrianto ◽  
Moedrik Tamam ◽  
Nyoman Suci Widyastiti

Background Blood transfusion remains the main therapy for anemia in β thalassemia major patients. However, frequent transfusions can cause oxidative stress in response to iron overload. Vitamin E is considered to be the best lipid-soluble exogenous antioxidant in humans. It can protect phospholipid membrane from peroxidarion. Erythrocyte osmotic fragility is a useful test to assess for the improvement of red blood cells in thalassemia patients after vitamin E supplementation.Objective To investigate the effect of vitamin E for improving erythrocyte osmotic fragility in β thalassemia major and for decreasing the need for frequent transfusions.Methods T his was a double blind placebo controlled randomized clinical trial on children aged 2-14 years with thalassemia major who received frequent blood transfusions. Fifty subjects were divided into 2 groups: group I with vitamin E supplementation and group II with placebo, as a control group, for a period of 1 month. Pre- and post-treatment data on erythrocyte osmotic fragility and hemoglobin level were analyzed with non-paired T-test.Results Improved erythrocyte osmotic fragility was found: in group I, pre-treatment 31.59 (SD 6.342)% to post-treatment 38.08 (SD 7.165)%, compared to the control group pre-treatment 34.40 (SD 6.985)% to post-treatment 29.26 (SD 9.011)% (P=0.0001). Comparison of the mean delta Hb level in group  I was 0.94 (SD 0.605) gr% and that of group II was - 0.23 (SD 1.199) gr% (P=0.0001).Conclusion Vitamin E supplementation improves erythrocyte fragility and Hb level in β thalassemia major pediatric patients.


2021 ◽  
Vol 22 (14) ◽  
pp. 7307
Author(s):  
Ilya S. Zhukov ◽  
Larisa G. Kubarskaya ◽  
Inessa V. Karpova ◽  
Anastasia N. Vaganova ◽  
Marina N. Karpenko ◽  
...  

Trace amine-associated receptors (TAARs) are a group of G protein-coupled receptors that are expressed in the olfactory epithelium, central nervous system, and periphery. TAAR family generally consists of nine types of receptors (TAAR1-9), which can detect biogenic amines. During the last 5 years, the TAAR5 receptor became one of the most intriguing receptors in this subfamily. Recent studies revealed that TAAR5 is involved not only in sensing socially relevant odors but also in the regulation of dopamine and serotonin transmission, emotional regulation, and adult neurogenesis by providing significant input from the olfactory system to the limbic brain areas. Such results indicate that future antagonistic TAAR5-based therapies may have high pharmacological potential in the field of neuropsychiatric disorders. TAAR5 is known to be expressed in leucocytes as well. To evaluate potential hematological side effects of such future treatments we analyzed several hematological parameters in mice lacking TAAR5. In these mutants, we observed minor but significant changes in the osmotic fragility test of erythrocytes and hematocrit levels. At the same time, analysis of other parameters including complete blood count and reticulocyte levels showed no significant alterations in TAAR5 knockout mice. Thus, TAAR5 gene knockout leads to minor negative changes in the erythropoiesis or eryptosis processes, and further research in that field is needed. The impact of TAAR5 deficiency on other hematological parameters seems minimal. Such negative, albeit minor, effects of TAAR5 deficiency should be taken into account during future TAAR5-based therapy development.


Sign in / Sign up

Export Citation Format

Share Document